



Press Release

A €11M order backlog for 2014, more than doubled as compared to 2013.

Award of 5 new projects for image interpretation and management in clinical trials totalling €3.24M.

- ✓ A €11M order backlog as of December 31, 2014 representing an increase of +134% as compared to 2013,
- ✓ New projects awarded* for the interpretation and management of medical images for two phase III studies for non-small cell lung cancer, a phase II study for breast cancer, a phase I/II study for colorectal cancer and a phase I study for solid tumor cancers.

SOPHIA ANTIPOLIS, France - February, 17 2015 - MEDIAN Technologies (ALMDT.PA), a leading medical imaging solutions and service provider for image interpretation and management in oncology clinical trials, cancer screening programs and routine practice in oncology, announced today a €11M backlog as of December 31, 2014 (vs €4,7M as of December 31, 2013). MEDIAN Technologies has been selected to provide imaging solutions and services for five new clinical studies in oncology for a total amount of approximately €3.24M:

- A phase III study (NSCLC) for a total of €1.2M
- A phase III study (NSCLC) for a total of €731K
- A phase II study (breast cancer) for a total of €408K
- A phase I/II study (colorectal cancer) for a total of €307K
- A phase I study (solid tumors) for a total of €593K.

“We are particularly proud that we have been awarded these new projects. These awards are a concrete illustration of MEDIAN’s capacity to penetrate new client accounts and also to generate repeat business through renewed confidence from existing clients”, said Jerome Windsor, VP Business Development Pharma. *“These trials are sponsored by internationally known biotechnology companies and major pharmaceutical companies, one of which is predominant in Asia”.*

“For the period September to December 2014 we have been awarded projects for a value of €7.2M” underlined Fredrik Brag, CEO of MEDIAN. *“Together with our €11M order backlog at the end of the fiscal year it demonstrates our business model efficiency,”* he added.

(*) A project award is a notification announcing that the company's solution has been chosen for a specific project. This should result in a firm contract within 18 months, subject to the confirmation of clinical results upstream.



MEDIAN

About MEDIAN Technologies: www.mediantechologies.com

ALMDT
LISTED
ALTERNEXT



Contacts

MEDIAN Technologies Fredrik Brag, CEO +33.4.92.90.65.82 fredrik.brag@mediantechnologies.com	Press ALIZE RP Caroline Carmagnol Sophie Colin +33.1.44.54.36.66 median@alizerp.com	Investors ACTIFIN Ghislaine Gasparetto ggasparetto@actifin.fr +33.1.56.88.11.11
--	--	---